Theravance Biopharma Receives FDA Fast Track Designation for TD-8954 for Use With Enteral Feeding in Critically Ill Patients
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/9/2026
- S&P 500 falls as AI worries hit software makers
- Brent crude hits six-week high near $97 as Houthi strike targets Saudi Aramco
- Qualcomm stock surges 9.5% on Amazon AI deal & 25M share warrant
- Energy stocks rise premarket as oil prices climb on Middle East supply fears
- Novartis shares plunge 10% as failed drug trial clouds growth outlook
- Harry and Meghan surprised by King Charles' letter on their status
- Citi initiates UiPath coverage with Buy rating and $23 target
- S&P 500 falls as AI worries hit software makers
- WestPark Capital Starts Akebia Therapeutics (AKBA) at Buy
- After an 18% summer selloff in chip stocks, Citi asks what comes next
- After-Hours Movers: LULU, IOT, PATH, DOCU, ASAN, GWRE, ZS, PL, SWBI, OXM
- After-Hours Movers: AVGO, SNOW, HPE, NTAP, NTSK, CHPT, FIVE, TLYS, PVH, RARE
- After-Hours Movers: DELL, PANW, GTLB, CRDO, MDB, HPE, SMCI
- After-Hours Movers: WDAY, ADSK, S, RBRK, MRVL, ULTA, GAP, AFRM
- After-Hours Movers: NVDA, CRM, SNPS, CRWD, OKTA, NTNX
Theravance Biopharma (TBPH) Tops Q2 EPS by 9c
August 10, 2015 4:22 PM EDTTheravance Biopharma (NASDAQ: TBPH) reported Q2 EPS of ($1.42), $0.09 better than the analyst estimate of ($1.51). Revenue for the quarter came in at $7.1 million versus the consensus estimate of $4.25 million.
Rick E Winningham, Chairman and Chief Executive Officer, commented: "In the first half of 2015, we have focused on executing our strategies to advance TD-4208 to a registrational Phase 3 program, creating an acute care commercial organization in the U.S., while positioning VIBATIV (telavancin) as an important treatment for patients with life-threatening infections, and advancing our two high-value research programs towards the clinic. We are... More
Theravance Biopharma (TBPH) Announces Receipt of FDA Fast-Track Designation for TD-8954 With Enteral Feeding in Critically Ill Patients
August 6, 2015 8:06 AM EDTTheravance Biopharma (NASDAQ: TBPH) announced that the U.S. Food and Drug Administration (FDA) granted Fast Track Designation to TD-8954 for short-term use with enteral feeding to achieve early nutritional adequacy in critically ill patients at high nutritional risk. TD-8954 is a selective 5-HT4 receptor agonist being evaluated for potential use in the treatment of gastrointestinal motility disorders, including enteral feeding intolerance (EFI). Importantly, there are currently no FDA-approved therapies for EFI, leaving the approximately one million Americans who suffer from the... More
